Four days ago — on June 10, 2026 — bellwether fact discovery officially closed in the ten judge-selected test cases at the heart of the hair relaxer lawsuit 2026 litigation. That single deadline marks the most consequential procedural inflection point the MDL has reached since consolidation, and it sets the stage for a November 16, 2026 summary judgment showdown that could define settlement values for more than 11,500 pending claims. Here is everything you need to know about where the litigation stands right now.
MDL 3060 by the Numbers: Scale, Scope, and Why It Matters
MDL 3060 — formally styled In re Hair Relaxer Marketing Sales Practices and Products Liability Litigation — is consolidated in the Northern District of Illinois before Judge Mary M. Rowland. As of May 2026, federal court MDL statistics confirm the docket has grown to 11,526 active lawsuits, with 15,504 total filings on record including resolved matters. That volume makes MDL 3060 the fifth-largest active MDL in the entire federal system as of early 2026 — a staggering concentration of cases alleging that chemical hair relaxers caused uterine cancer, endometrial cancer, and ovarian cancer in women who used them regularly over years or decades.
The litigation traces directly to a landmark 2022 study by the NIH National Institute of Environmental Health Sciences (NIEHS), which analyzed data from the Sister Study — a cohort tracking more than 33,000 women. Researchers found that women who used chemical hair-straightening products more than four times per year faced a 2.05x to 2.55x increased risk of uterine cancer compared to non-users. Approximately 60% of the study participants who reported using relaxers were Black women, a demographic disproportionately affected by both the products and the cancers at issue.
| MDL 3060 Key Metric | Figure | Source / Date |
|---|---|---|
| Active lawsuits (MDL docket) | 11,526 | Motley Rice, June 2026 |
| Total filings including resolved | 15,504 | MDL Update, April 2026 |
| Federal MDL size rank (active) | 5th largest | LlamaLab, March 2026 |
| NIH uterine cancer risk increase (frequent users) | 2.05x – 2.55x | Mass Tort Ad Agency, May 2026 |
| Black women in NIH relaxer-user cohort | ~60% | LlamaLab, March 2026 |
| Bellwether cases (judge-selected) | 10 | DrugWatch, April 2026 |
| Bellwether fact discovery close date | June 10, 2026 | MDL Update, April 2026 |
| Summary judgment / Daubert deadline | November 16, 2026 | Verus LLC / MDL Update |
| First federal bellwether trials (projected) | Mid-2027 | Miller & Zois, May 2026 |
The Defendants and the Chemicals: Who Is Being Sued and Why
The hair relaxer lawsuit 2026 targets some of the largest consumer product companies in the world. Key defendants include L’Oréal USA (maker of Dark & Lovely and Mizani relaxers), Revlon (Creme of Nature), SoftSheen-Carson, Namaste Laboratories, Strength of Nature, Godrej Consumer Products, and Unilever. Plaintiffs allege these companies knew — or should have known — that their formulations contained endocrine-disrupting and carcinogenic chemicals yet failed to warn consumers of the risks.
The chemical allegations at the core of the hair relaxer lawsuit 2026 center on phthalates, parabens, formaldehyde, bisphenol-A (BPA), and cyclosiloxanes — compounds that plaintiffs’ experts argue disrupt hormonal function and elevate cancer risk with repeated scalp exposure. The U.S. Food and Drug Administration proposed a rule to ban formaldehyde in hair straighteners but failed to finalize the regulation by its own stated deadline — a regulatory gap that plaintiffs argue demonstrates the known hazard companies chose to ignore.
Women who regularly used chemical relaxers and were subsequently diagnosed with uterine cancer, endometrial cancer, or ovarian cancer are the primary eligible claimants. If you used relaxers long-term and have sustained serious injury, understanding the full scope of compensation — including economic and non-economic damages — is critical. A personal injury settlement calculator can help you begin benchmarking what a claim of this nature may be worth before you speak with counsel.
Judge Rowland’s Unprecedented Bellwether Move: What It Signals
Perhaps the most telling development of the entire hair relaxer lawsuit 2026 docket is Judge Rowland’s April 2026 decision to personally hand-pick all ten bellwether cases after outright rejecting the selections submitted by both plaintiffs and defendants. This is a rare and deliberate judicial maneuver. In most MDL proceedings, judges accept or negotiate between the parties’ proposed test cases. By seizing that process herself, Judge Rowland signaled that she intends these bellwethers to represent a genuinely representative cross-section of the litigation — not cases cherry-picked by either side to skew early verdicts toward their preferred narrative.
One case that survived into the bellwether pool from the defendants’ preferred selections is Rosa Hauck, a plaintiff who used L’Oréal hair relaxers for nearly 20 years. Her case is considered favorable to the defense because of her specific exposure timeline, but it now sits alongside nine other cases Judge Rowland determined independently. With bellwether fact discovery now closed as of June 10, 2026, both sides have the full evidentiary record in hand for those ten cases — depositions, medical records, product use histories, and expert foundations. The litigation clock is now running hard toward November 16.
The Daubert Battle: Can Plaintiffs’ Science Survive Federal Scrutiny?
The most legally consequential pending matter in the hair relaxer lawsuit 2026 litigation is the set of Daubert/Rule 702 motions filed by defendants on April 1, 2026. These motions ask Judge Rowland to exclude plaintiffs’ general causation experts — the scientists who would testify at trial that chemical relaxers cause uterine and ovarian cancer — on the grounds that their methodology does not meet the federal admissibility standard established under Daubert v. Merrell Dow Pharmaceuticals, Inc..
To prepare for this ruling, Judge Rowland held a Science Day hearing on January 8, 2026 — a structured educational session allowing both sides’ experts to present the underlying science to the court before formal briefing began. General causation expert discovery closed March 2, 2026, and the Daubert motions are now fully briefed and pending. If Judge Rowland excludes plaintiffs’ general causation experts, the entire MDL could effectively collapse — no causation testimony means no viable claims. If she admits the testimony, the litigation moves forward toward trials and dramatically increased settlement pressure on defendants. This is the highest-stakes ruling still outstanding in the hair relaxer lawsuit 2026 proceedings.
For women whose cancers were caused by defective product formulations knowingly sold to consumers, this type of litigation sits at the intersection of products liability and what courts sometimes treat similarly to medical malpractice calculator scenarios — where the harm is biological, latent, and caused by a party with superior knowledge of the risk.
New Medical Monitoring Class Action and the Road to Trial
The hair relaxer lawsuit 2026 landscape expanded significantly in March 2026 with the filing of a new medical monitoring class action targeting women who used chemical relaxers regularly but have not yet been diagnosed with cancer. This separate action seeks court-ordered programs to fund ongoing cancer screening — including regular ultrasounds and endometrial biopsies — for at-risk former users. Medical monitoring claims do not require a present injury, only an elevated risk requiring surveillance, which substantially broadens the potential plaintiff class beyond those already diagnosed.
On the evidentiary front, two notable discovery rulings have shaped the record. Judge Rowland denied Revlon’s motion to subpoena the NIH for internal Sister Study documents, writing that “Revlon has not shown the relevance of the expansive categories of documents it seeks.” Separately, L’Oréal filed a Hague Convention motion seeking corporate documents from its French parent company, L’Oréal S.A. — a request that could yield internal communications about product safety assessments conducted overseas. Special Master Ellen K. Reisman continues to oversee parallel settlement discussions, but no settlement agreement has been reached as of this writing.
While the first federal bellwether trials are not expected until mid-2027, state court cases in Illinois, Georgia, New York, Pennsylvania, and Delaware are moving on independent tracks and may produce verdicts — or settlement leverage — before the federal MDL reaches trial. In the tragic event that a woman dies from relaxer-related cancer before her case resolves, surviving family members should understand the full range of remedies available through a wrongful death calculator to estimate potential compensation for their loss.
Frequently Asked Questions: Hair Relaxer Lawsuit 2026
Who qualifies to file a hair relaxer lawsuit in 2026?
Women who used chemical hair relaxers or straighteners regularly — generally defined as more than four times per year over multiple years — and who were subsequently diagnosed with uterine cancer, endometrial cancer, or ovarian cancer may qualify to file a claim in the hair relaxer lawsuit 2026 MDL or in state court. The qualifying cancers must have a plausible timeline connecting long-term relaxer exposure to the diagnosis. Women who have not yet been diagnosed but used relaxers extensively may also be eligible to participate in the newly filed March 2026 medical monitoring class action.
What is the current status of MDL 3060 as of June 2026?
As of June 2026, MDL 3060 contains 11,526 active lawsuits before Judge Mary M. Rowland in the Northern District of Illinois. Bellwether fact discovery in the ten judge-selected test cases closed on June 10, 2026. Daubert motions challenging plaintiffs’ general causation experts were filed April 1, 2026, and are fully briefed and pending. The next hard deadline is November 16, 2026, for summary judgment and non-causation Daubert motions. The first federal trials are projected for mid-2027, with no global settlement reached yet.
What chemicals in hair relaxers are alleged to cause cancer?
Plaintiffs in the hair relaxer lawsuit 2026 allege that the following chemical compounds in relaxer formulations elevate cancer risk: phthalates (endocrine disruptors linked to hormonal cancers), parabens (preservatives with estrogenic activity), formaldehyde and formaldehyde-releasing agents (known carcinogens), bisphenol-A (BPA), and cyclosiloxanes. The NIH Sister Study found that women who used chemical straighteners more than four times per year faced a 2.05x to 2.55x increased risk of uterine cancer compared to non-users, supporting the biological plausibility of these chemical mechanisms.
Why did Judge Rowland personally select the bellwether cases instead of the parties?
Judge Rowland rejected both parties’ proposed bellwether selections in April 2026 and personally hand-picked all ten test cases — an unusual step that signals her intent to ensure the bellwethers are genuinely representative of the broader MDL rather than strategically curated by either side. Bellwether cases serve as trial runs whose verdicts inform settlement negotiations across the entire docket. When parties select their own, they tend to choose cases most favorable to their position, distorting the data. By controlling selection herself, Judge Rowland is attempting to produce outcomes that more accurately reflect the realistic litigation range across 11,500-plus claims.
How much could a hair relaxer lawsuit settlement be worth in 2026?
No global settlement has been reached in the hair relaxer lawsuit 2026 MDL as of June 2026, so no official settlement grid exists. Individual case values will depend on the severity of the cancer diagnosis (stage and type), the duration and frequency of relaxer use, the plaintiff’s age and economic losses, treatment costs, and pain and suffering. Uterine and ovarian cancer diagnoses involving aggressive treatment, recurrence, or long-term disability typically command higher values. Bellwether trial verdicts in mid-2027 will be the primary driver of settlement negotiations and compensation tiers across the MDL.
Legal Disclaimer: The content on this page is provided for general informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction for guidance specific to your situation.
Related reading: personal injury settlement calculator
Related reading: medical malpractice calculator
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.